Soluble Klotho causes hypomineralization in Klotho-deficient mice by Minamizaki, Tomoko et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Soluble Klotho causes hypomineralization in Klotho-deficient mice
Auther(s) Minamizaki, Tomoko; Konishi, Yukiko; Sakurai, Kaoru;Yoshioka, Hirotaka; Aubin, Jane E.; Kozai, Katsuyuki;
Yoshiko, Yuji
Citation Journal of Endocrinology , 237 (3) : 285 - 300
Issue Date 2018-06
DOI 10.1530/JOE-17-0683
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00049037
Right This document is the Accepted Manuscript version of aPublished Work that appeared in final form in Journal of
Endocrinology, copyright © Society for Endocrinology after
peer review and technical editing by the publisher. To
access the final edited and published work see https://
doi.org/10.1530/JOE-17-0683. This is not the published
version. Please cite only the published version. この論文は
出版社版でありません。引用の際には出版社版をご確認、ご利用
ください。
Relation
  
1 
 
Soluble Klotho causes hypomineralization in Klotho-deficient mice 
 
Tomoko Minamizaki,1* Yukiko Konishi,1,2* Kaoru Sakurai,1,2 Hirotaka Yoshioka,1 Jane E. 
Aubin,3 Katsuyuki Kozai,2 Yuji Yoshiko1 
 
1 Department of Calcified Tissue Biology, School of Dentistry, Hiroshima University 
Graduate School of Biomedical & Health Sciences, 1-2-3, Kasumi, Minami-ku, Hiroshima 
734-8553, Japan 
2 Department of Pediatric Dentistry, School of Dentistry, Hiroshima University Graduate 
School of Biomedical & Health Sciences, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-
8553, Japan 
3 Department of Molecular Genetics, University of Toronto, 1 King’s College Circle, 
Toronto, Ontario M5S 1A8, Canada 
 
*Tomoko Minamizaki and Yukiko Konishi contributed equally to this work. 
 
Corresponding author 
Yuji Yoshiko, Ph.D. 
Department of Calcified Tissue Biology, School of Dentistry, Hiroshima University 
Graduate School of Biomedical & Health Sciences, 1-2-3, Kasumi, Minami-ku, 
Hiroshima 734-8553, Japan 
Tel.: +81 82 257 5620 
Fax: +81 82 257 5621 
  
2 
 
E-mail: yyuji@hiroshima-u.ac.jp 
 
Running headline:  sKL causes hypomineralization in kl/kl mice 
  
3 
 
Abstract 
The type I transmembrane protein aKlotho (Klotho) serves as a coreceptor for the 
phosphaturic hormone fibroblast growth factor 23 (FGF23) in kidney, while a truncated 
form of Klotho (soluble Klotho, sKL) is thought to exhibit multiple activities, including 
acting as a hormone, but whose mode(s) of action in different organ systems remains to 
be fully elucidated. FGF23 is expressed primarily in osteoblasts/osteocytes and 
aberrantly high levels in the circulation acting via signaling through an FGF receptor 
(FGFR)-Klotho coreceptor complex cause renal phosphate wasting and osteomalacia. 
We assessed the effects of exogenously added sKL on osteoblasts and bone using 
Klotho-deficient (kl/kl) mice and cell and organ cultures. sKL induced FGF23 signaling 
in bone and exacerbated the hypomineralization without exacerbating the 
hyperphosphatemia, hypercalcemia and hypervitaminosis D in kl/kl mice. The same 
effects were seen in rodent bone models in vitro, in which we also detected formation of 
a sKL complex with FGF23-FGFR and decreased Phex (gene responsible for X-linked 
hypophosphatemic rickets (XLH)/osteomalacia) expression. Further, sKL-FGF23-
dependent hypomineralization in vitro was rescued by soluble PHEX. These data 
suggest that exogenously added sKL directly participates in FGF23 signaling in bone 
and that PHEX is a downstream effector of the sKL-FGF23-FGFR axis in bone.  
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Introduction 
aKlotho (Klotho) is a type I transmembrane protein with a large extracellular domain, a 
single-pass membrane-spanning segment, and a short intracellular carboxyl terminus without 
any phosphorylation sites. Klotho hypomorphic (kl/kl) mice display various anomalies 
resembling a human senescence-related phenotype, including skin and muscle atrophy, 
vascular calcification, and premature death (Kuro-O et al. 1997). In humans, a homozygous 
missense mutation (H193R) in KLOTHO is involved in severe tumoral calcinosis with dural 
and carotid artery calcifications (Ichikawa et al. 2007). KLOTHO gene polymorphisms 
(G395A in the promoter region and C1818T in exon 4) have also been associated with bone 
mineral density and multiple pathophysiologies in humans (Kawano et al. 2002, Shimoyama 
et al. 2009). 
Klotho is highly expressed in kidneys and forms a complex with and converts canonical 
fibroblast growth factor receptors (FGFRs), in particular FGFR1, into a specific receptor for 
fibroblast growth factor 23 (FGF23), a phosphaturic hormone (ADHR Consortium 2000, 
Kurosu et al. 2006, Urakawa et al. 2006). It is therefore perhaps not surprising that loss of 
function of Klotho shares many common features with loss of function of FGF23 in mice, 
including increased serum levels of phosphate (Yoshida et al. 2002, Shimada et al. 2004b). 
FGF23, secreted primarily by osteoblasts and osteocytes (Riminucci et al. 2003, Yoshiko et 
al. 2007b), circulates in blood and acts together with membrane Klotho in renal tubules to 
suppress phosphate reabsorption and vitamin D3 activation (Shimada et al. 2004a, Shimada et 
al. 2004b, Larsson et al. 2004). Consistent with this, kl/kl mice have extremely high levels of 
serum FGF23, and exhibit hyperphosphatemia, hypervitaminosis D, and hypophosphatemic 
disorders (Segawa et al. 2007). 
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The widespread effects of Klotho deficiency on tissues/organs not expressing Klotho, such as 
seen in kl/kl mice and conditions of Klotho haploinsufficiency in humans have suggested that 
Klotho functions through a circulating and, as yet, undefined, hormonal factor(s) (Kuro-O et 
al. 1997, Kawaguchi et al. 1999, Kawano et al. 2002, Shimoyama et al. 2009). Three Klotho 
protein types have been identified: a full-length transmembrane Klotho, a truncated soluble 
Klotho (sKL), and a secreted Klotho (Kuro-O et al. 1997, Matsumura et al. 1998, Wang & 
Sun 2009, Xu & Sun 2015). All types have been detected in humans and mice, but only the 
transmembrane and soluble Klotho proteins have been detected in rats (Wang & Sun 2009, 
Matsumura et al. 1998). sKL, arising from cleavage (shedding) of membrane Klotho by the 
metalloproteinase (ADAM) family members ADAM10 and ADAM17 (Chen et al. 2007) and 
a secreted Klotho by alternative splicing of Klotho are thought to be released into the 
circulation (Matsumura et al. 1998, Wang & Sun 2009, Xu & Sun 2015), but the function of 
sKL and secreted Klotho is not clear. Exact concentrations of serum sKL also remain 
uncertain, in part due to different forms of sKL and secreted Klotho and differences measured 
with different immunoassays, but levels of less than a few hundred nanograms per milliliter 
are seen in mice and humans (Kurosu et al. 2005, Pedersen et al. 2013). Treatment with sKL 
or transgenic overexpression of sKL extends mouse lifespan with multiple effects on 
insulin/insulin-like growth factor-I, TGF-ß and Wnt signaling (Kurosu et al. 2005, Liu et al. 
2007, Chen et al. 2013), interaction with vascular endothelial growth factor receptor (VEGF)-
2 and endothelial transient-receptor potential canonical Ca2+ channels to regulate Ca2+ influx 
in aorta (Kusaba et al. 2010), and hydrolyzation of the glycosylated transient receptor 
potential ion channel TRPV5 in kidney (Chang et al. 2005, Wolf et al. 2014).  
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Previously, we demonstrated hypomineralization in osteoblast cultures overexpressing 
FGF23 (Wang et al. 2008). sKL has also been shown to interact with FGF23 (Kawai et al. 
2013) and decrease chondrocyte proliferation via FGFR3 but increase proliferation while 
inhibiting differentiation-mineralization via FGFR1 in the MC3T3-E1 osteoblastic cell model 
(Shalhoub et al. 2011, Kawai et al. 2013). To further assess whether sKL contributes to 
FGF23 actions in bone, and to eliminate confounding effects of membrane-associated Klotho, 
we used kl/kl mice supplemented with and without sKL. We found that sKL promotes FGF23 
signaling in kl/kl bone and downregulates Phex, which contributes, at least in part, to sKL-
FGF23-induced inhibition of bone mineralization. 
 
Materials and Methods  
Animals  
Klotho mutant mice (kl/+; CREA Japan, Tokyo, Japan), C57BL/6J mice, and timed-pregnant 
Wistar rats (Charles River Laboratories Japan, Yokohama, Japan) use and procedures were 
approved by the Institutional Animal Care and Use Committee at Hiroshima University 
(Approval #A09-36). Genotyping of kl/kl mice and wild type (WT) littermates was performed 
as described previously (Brownstein et al. 2010). 
Male C57BL/6J mice (age, 4 wk) were treated with 1a,25-dihydroxyvitamin D3 (1,25 D; 6 
µg/kg in ethanol:polyethylene glycol at 1:4 [vol/vol]; Enzo Life Sciences, Farmingdale, NY) 
subcutaneously once per day for 2 d, followed 24 h later by a single intravenous injection of 
sKL (10 µg/kg in PBS) or vehicle (PBS) alone (Hines et al. 2004; Kawai et al. 2013). Sera, 
kidneys, and bones were harvested 2 h after the sKL injection. Male kl/kl and age-matched 
  
7 
 
WT mice were treated with a subcutaneous sKL (or vehicle) injection (10 µg/kg; R&D 
Systems, Minneapolis, MN) in 0.5% atelocollagen as carrier in PBS (Koken, Tokyo, Japan) 
into the dorsum every second day from postnatal day 10 (P10) to P22 (group kl/kl + sKL). 
Calcein (10 mg/kg in 2% sodium bicarbonate) was injected intraperitoneally twice, at P14 
and P20. All samples were collected at P22.  
 
Cell and organ cultures 
The reagents used (final concentrations given in parentheses) were: 1,25D (1–10 nM); FGF23 
and sKL (500 ng/ml each, unless otherwise specified; R&D Systems); MAPK inhibitors (for 
ERK, U0126; for JNK, dicumarol; and for p38MAPK, SB203580; 10 µM each). All other 
chemicals, unless otherwise specified, were purchased from Sigma-Aldrich (St. Louis, MO). 
These reagents were dissolved as appropriate in ethanol, PBS, or DMSO, and maintained at 
−20 or −80°C until use. Heparin (1 µg/ml) was included along with FGF23 when cells were 
maintained under serum-deprived conditions (see below). 
We isolated calvarial cells from 21-d-old fetal rats or newborn kl/kl and WT mice as 
described previously (Wang et al. 2008; Minamizaki et al, 2009). Cells were cultured in α-
MEM containing 10% fetal bovine serum (FBS; HyClone; GE Healthcare Life Sciences, 
Logan, UT) and 50 µg/ml ascorbic acid (osteogenic medium). Unless otherwise stated, cells 
adapted to serum-deprived conditions (0.1% FBS in αMEM) for 24 h were used for 
mineralization studies; to induce matrix mineralization, cells were treated with 2 mM ß-
glycerophosphate for the last 24 h of culture and stained for ALP/von Kossa, followed by 
quantification using imageJ (Bellows et al. 1986). We have previously reported the temporal 
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expression profiles of osteoblast markers during differentiation and mineralization in rat 
calvarial (RC) cell cultures (Minamizaki et al. 2009). 
RC cells transfected with human FGF23 recombinant adenoviruses (Adv-hFGF23) or 
adenoviruses expressing β-galactosidase (Adv-βgal; BD Biosciences, San Jose, CA) were 
obtained as described elsewhere (Wang et al. 2008). 
For organ culture, two fragments (approximately 1.5 ´ 3 mm) randomly selected from 
parietal bones of WT or kl/kl mice were placed on a cell culture insert in a well (BD 
Biosciences) in BGJb medium supplemented with 0.1% bovine serum albumin and 
recombinant human BMP-2 (50 ng/ml; PeproTech, Rocky Hill, NJ) for 24 h, followed by 
fresh medium with or without sKL. 
 
FGF23, 1,25D, phosphate, and calcium concentrations 
We measured FGF23 concentrations in sera, conditioned media, and/or lysates of kidneys 
and bones by using an FGF23 ELISA kit (intact FGF23, Kainos, Tokyo, Japan). Serum 
1,25D and phosphate/calcium concentrations were quantified using a radioimmunoassay 
(TFB, Tokyo, Japan) and calorimetric determination kits (Wako Pure Chemical, Osaka, 
Japan), respectively. Protein concentrations were determined using the BCA protein assay 
(Thermo Fisher Scientific, Waltham, MA). 
 
Western blotting  
Lysates or eluates from immunomagnetic separation were subjected to SDS-PAGE and 
blotted onto polyvinylidene difluoride membranes, which were incubated with primary 
antibodies (polyclonal antibodies against FGF23, phosphorylated and non-phosphorylated 
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ERK1/2; 1:1000; Santa Cruz) and then HRP-conjugated secondary antibodies (1:2000; Santa 
Cruz). 
 
Reverse transcription and PCR analysis 
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), reverse 
transcribed (ReverTra Ace®; Toyobo, Osaka, Japan) and subjected to quantitative real-time 
PCR (StepOnePlus; Life Technologies, Carlsbad, CA) as described (Yoshiko et al. 2007a, 
Faul et al. 2011). ß-actin (in vivo) or ribosomal protein L32 (in vitro) was used as internal 
control. Primer and amplicon information is in Table 1. 
 
Histological and morphological assays 
Tissues were fixed in 4% paraformaldehyde in PBS and plastic sections prepared according 
to the manufacturer’s instructions. Bone mineralization was evaluated using calcein double-
labeling (Choi et al. 2017). Plastic sections were also carbon-coated and elemental mapping 
of magnesium, calcium, and phosphorus was performed using electron probe microanalysis 
with a beam current of 20 nA and an accelerating voltage of 15 kV with an integration time 
of 0.05 s at each pixel (JXA-8200; JEOL, Tokyo, Japan) (Suzuki et al. 2008). The RGB (red, 
green, blue) color intensity was quantified by ImageJ. Decalcified paraffin sections (10% 
EDTA in PBS) were used for hematoxylin and eosin or immunofluorescence staining. Frontal 
sections (thickness, 5 µm), approximately 2-mm from the sagittal suture, were used for 
histomorphometry. Sections pretreated with Dako® protein block (Dako, Glostrup, Denmark) 
were incubated with a mixture of polyclonal antibodies against FGF23 and pERK1/2 or with 
polyclonal antibodies against PHEX (1:60; Santa Cruz Biotechnology, Dallas, TX) at 4°C 
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overnight, followed by incubation with a mixture of Cy2- and/or Cy3-conjugated (1:400; 
Jackson ImmunoResearch Laboratories, West Grove, PA) or Alexa FluorÒ 594 (1:500; 
ThermoFisher Scientific, Waltham, MA)-conjugated secondary antibodies for 1 h at room 
temperature. FGF23- and pERK-positive areas on the sections were quantified by ImageJ. 
 
Immunoprecipitation 
Cell lysates, prepared in 1% IGEPAL CA630 and 50 mM Tris HCl (pH 8.0), were incubated 
with protein G-conjugated magnetic microbeads (Miltenyi Biotec Inc., San Diego, CA) plus 
mouse monoclonal antibody against FGFR1 or control IgG for 30 min on ice under rotary 
agitation, followed by rinsing and elution to obtain immune complexes in accordance with 
the manufacturer’s recommendations. 
 
DNA microarray 
Total RNA (1 μg; evaluated by RIN value) was extracted from Adv-hFGF23- or Adv-βgal-
transfected RC cells (n=3 replicates for each) and used for generation of second-strand 
cDNA, and cRNA was amplified with the Oligo dT primer, biotinylated and fragmented with 
One-Cycle Target Labeling and control reagents (Affymetrix, Santa Clara, CA), followed by 
hybridization to the GeneChip Rat Genome 230 2.0 Array overnight according to the 
manufacturer's protocol. 
 
Statistical analysis  
Data are presented as mean ± SD (n = 3–4 in vitro, n = 5–9 in vivo). Experiments were 
repeated a minimum of two times. Statistical differences were analyzed with one-way 
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ANOVA using post-hoc Tukey’s test for multiple comparisons and t-tests for between group 
comparisons. 
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Results 
sKL is involved in FGF23 signaling in kl/kl bones 
As expected, serum FGF23 (full length intact FGF23) level was much higher in kl/kl 
compared to WT mice (Fig. 1A, Supplemental Fig. 1A), as were levels of serum calcium 
(Fig. 1B), phosphate (Fig. 1C) and 1a,25-dihydroxyvitamin D3 (1,25D) (Fig. 1D). Fgf23 
expression (Fig. 1E) and accumulation (Fig. 1F) in bone and kidney was also higher in kl/kl 
compared to WT mice. Notably, administration of sKL to kl/kl mice increased ERK1/2 
phosphorylation (pERK1/2) in bone but not kidney (Fig. 1G), and did not change serum 
parameters tested. As for the renal FGF23 target genes, Cyp27b1 levels were higher in kl/kl 
than in WT mice (Fig. 1H), while Slc34a1 (Fig. 1I) and Slc34a3 (Fig. 1J) were equally 
expressed among all groups. Neither the Klotho deficiency in kl/kl mice nor sKL 
supplementation had any significant effect on the levels of Galnt 3 mRNA whose product (N-
acetylgalactosaminyltransferase 3) O-glycosylates FGF23 to prevent proteolytic processing 
by the subtilisin-like proprotein convertase FURIN in bone and kidney (Fig. 1K) (Kato et al. 
2006, Frishberg et al. 2007, Tagliabracci et al. 2014). Furin mRNA levels (Fig. 1L) was 
significantly higher in kidney but not bone of kl/kl mice. sKL had no effect on the reduced 
weight gain exhibited by kl/kl compared to WT mice (Supplemental Fig. 1B). Short term 
treatment of WT mice with sKL had no effect on serum parameters, gene expression in 
kidney or bone, or bone parameters (see below; data not shown).  
 
sKL potentiates ERK signaling in bones of normal Klotho-expressing mice treated with 
1,25D 
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To determine whether sKL elicits similar responses to those seen in kl/kl mice in normal 
Klotho-expressing mice treated with 1,25D, we treated C57BL/6J mice with 1,25D followed 
by a single injection of sKL. As expected (Kolek et al. 2005, Yamamoto et al. 2010), 1,25D 
increased not only Fgf23 expression (Fig. 2A) and accumulation (Fig. 2B) in bone, but also 
increased levels of serum FGF23 (Fig. 2C) and calcium (Fig. 2D). 1,25D treatment had no 
effect on serum phosphate levels (Fig. 2E), but decreased levels of the FGF23 target genes in 
kidney (see above) (Fig. 2F-H) and increased pERK1/2 in bone and kidney (Fig. 2I and J). 
Notably, the 1,25D-induced increase in pERK1/2 in bone was further enhanced by sKL 
treatment within 2 h (Fig 2I and J). Thus, exogenously added sKL activates the ERK pathway 
in not only kl/kl but also normal bone. 
 
sKL causes mineralization defects in kl/kl bones 
Given that sKL activated ERK1/2 in bone of kl/kl mice, we hypothesized that sKL might 
improve the skeletal anomalies seen in kl/kl mice. However, electron probe X-ray 
microanalysis of parietal bones revealed lower calcium and phosphorus, and higher 
magnesium signals in bones of sKL-treated kl/kl mice versus in WT or vehicle-treated kl/kl 
mice (Fig. 3A and Suppl. Fig. 2). Reduced calcein double-labeling (Fig. 3B) and increased 
osteoid thickness (Fig. 3C and D) paralleled the electron probe X-ray microanalysis data. 
sKL treatment had no detectable effect on osteoblast number (Fig. 3E), osteocyte number 
(Fig. 3F) or bone thickness (Fig.3G). Osteoblasts and osteocytes were markedly FGF23-
positive in kl/kl but not WT bone, with intense FGF23-pERK co-expression in bone of sKL-
treated mice (Fig. 4A). Concomitantly, the expression of the osteoblast/osteocyte marker 
genes (Fig. 4B-G) with the exception of Bglap (Fig. 4D) tended to be higher in kl/kl 
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compared to WT bone, with Spp1 (Fig. 4B), Dmp1 (Fig. 4E), Mepe (Fig. 4G) and Phex (Fig. 
4H) significantly higher; of these, only Phex was decreased significantly by sKL treatment. 
No significant changes were detectable in Fgfr1 mRNA expression under any condition. 
 
sKL directly promotes FGF23 signaling and hypomineralization of bone in vitro 
To determine whether sKL directly regulates FGF23-dependent signaling in bone, we 
assessed kl/kl and WT mouse calvaria cells in osteogenic medium in vitro. kl/kl calvaria cells 
exhibited intrinsic anomalies with fewer ALP-positive (ALP+) cells (Fig. 5A) and lower 
matrix mineralization (Fig. 5B) than their WT counterparts. FGF23 was very low to 
undetectable in both WT and kl/kl cells (Fig. 5C), with undetectable expression of Klotho but 
elevated levels of Fgf23 mRNA in bones (Fig. 5D). These results suggest that the intrinsic 
defects in kl/kl osteoblasts are independent of FGF23 levels. Consistent with this possibility, 
although FGF23 production was high in kl/kl up to at least 48 h in calvaria organ cultures 
(Fig. 5E), expression of early growth response-1 (Egr-1), another marker of FGF23 signaling 
(Kurosu et al. 2006) (Fig. 5F), and pERK1/2 (Fig. 5G) was increased in kl/kl calvaria organ 
cultures only on treatment with sKL. Similarly, Egr-1 expression (Fig. 5H) and ERK1/2 
activation (Fig. 5I) were seen in the rat calvaria (RC) cell osteogenic model only when sKL 
was used in combination with FGF23. These results indicate that sKL directly promotes 
FGF23 signaling in bones.  
 
Phex is a downstream effector of sKL-FGF23-FGFR signaling in osteoblasts  
To identify the gene(s) acting downstream of sKL-FGF23-FGFR signaling in osteoblasts-
osteocytes, we used the RC cell model during mineralization phase of culture (Minamizaki et 
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al. 2009). We first confirmed that endogenous FGF23 coprecipitated FGFR1 in the presence 
of sKL in RC cells pretreated with 1,25D (Fig. 5J). Second, we confirmed that matrix 
mineralization is defective in RC cells when they are treated with sKL plus FGF23 (Fig. 6A). 
Of more than 31,000 genes screened by microarray analysis, 52 genes were differentially 
expressed in sKL-FGF23-treated versus untreated RC cells; of these, 16 genes were 
downregulated (Table 2). Of these sixteen genes, only Phex has previously been implicated in 
bone mineralization, with Phex haploinsufficiency causing osteomalacia/X-linked 
hypophosphatemic rickets in mice and humans (Guo & Quarles 1997, Miao et al. 2001). 
qRT-PCR confirmed that sKL downregulated Phex in both RC cell culture (Fig. 6B) and kl/kl 
bone organ culture (Fig. 6C) models. As expected based on its activity to stimulate FGF23 
(Kolek et al. 2005, Yamamoto et al. 2010), 1,25D also downregulated Phex in the RC cell 
model (Fig. 6D). Treatment of RC cells with soluble PHEX (sPHEX) in the presence of sKL 
and FGF23 rescued the hypomineralization caused by sKL and FGF23 (Fig. 6E). Finally, the 
sKL-FGF23-induced hypomineralization of RC cell cultures was also rescued by U0126, an 
inhibitor of ERK activation involved FGF23 signaling, but not the c-Jun N-terminal kinase 
(JNK) inhibitor dicumarol or the p38 MAP kinase inhibitor SB203580 (Fig. 6F). Taken 
together, our findings suggest that sKL-FGF23 induces ERK1/2 activation in bone leading to 
downregulation of Phex and hypomineralization. 
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Discussion   
Much remains to be understood about the relationship between sKL, the Klotho-FGF23 axis 
and mineralization of bone. In this study, we assessed the effects of exogenously added sKL 
on bone and osteoblasts using Klotho-deficient (kl/kl) mice and cell and organ cultures. We 
found that sKL induced FGF23 signaling and ERK1/2 activation in bone and exacerbated the 
kl/kl hypomineralization defect without exacerbating the hyperphosphatemia, hypercalcemia 
or hypervitaminosis D seen in these mice. We also report that sKL formed a complex with 
FGF23 and FGFR, caused ERK1/2-dependent downregulation of Phex and that the sKL-
FGF23-dependent hypomineralization was rescued by treatment with soluble PHEX in vitro. 
These data suggest that exogenously added sKL participates directly in FGF23 signaling in 
bone and that PHEX is a downstream effector of the sKL-FGF23-FGFR axis in bone (Fig. 7). 
 
Interactions among the type I membrane protein Klotho, FGF23, and FGFR1 suggest that the 
target cells of FGF23 express Klotho, as seen in kidney (Kurosu et al. 2006, Urakawa et al. 
2006, Ben-Dov et al. 2007, Lindberg et al. 2014). Klotho expressed in osteocytes has been 
reported to play a key role in bone mineralization (Komaba et al, 2017), in spite of 500 times 
lower Klotho in bone than kidney (Rhee et al. 2011) and undetectable Klotho expression in 
osteoblasts (see Fig. 5). Such reports highlight the need to better understand the potential 
mechanisms by which FGF23 regulates bone mineralization. Consistent with several studies 
(Goetz et al. 2010, Shalhoub et al. 2011, Smith et al. 2012, Kawai M et al. 2013), we found 
that sKL participates in FGF23-dependent signaling, and in particular we report that sKL 
negatively regulates bone mineralization both in normal bone cell models and in the complete 
absence of Klotho in kl/kl mice. Taken together, the data raise questions about how 
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extensively sKL contributes to FGF23-dependent signaling in bones under normal and 
pathological conditions. The finding that Fgf23 expression in bones is dependent on the 
circadian clock system (Kawai et al. 2014) further highlights the need for additional studies. 
 
Although sKL forms a complex with FGF23 and FGFRs and subsequently promotes FGF23 
signaling in a variety of cells, including NIH3T3 cells treated with increasing concentrations 
of FGF23 and sKL (Smith et al., 2012) and human embryonic kidney 293 cells 
overexpressing FGF23 and sKL (Kawai et al. 2013), our relatively short-term treatment 
protocols with sKL inhibited bone mineralization without affecting renal FGF23 target genes 
or changing serum calcium and phosphate levels in the models used here. Similarly, short-
term treatment with sKL did not rescue serum phosphate levels or affect expression of renal 
FGF23 target genes in neonatal Hyp mice, a mouse model of XLH (Kawai et al. 2013) nor 
did sKL enhance the effect of FGF23 treatment alone in kidney slices ex vivo (Andrukhova et 
al, 2017). Longer-term administration (intraperitoneally) of sKL has also been shown to 
rescue ectopic calcification without changes in serum calcium and phosphate levels in kl/kl 
mice (Chen et al. 2013); whether short-term administration of sKL also has an inhibitory 
effect on ectopic mineralization in kl/kl mice seems plausible but remains to be determined. 
Indeed, chronic sKL overexpression driven by a liver-specific promoter in mice resulted in 
osteomalacia, although this was accompanied by hypophosphatemia, hypocalcemia and 
markedly increased FGF23, making it difficult to separate sKL effects in kidneys versus 
bones (Smith et al, 2012). Taken together, these results suggest that sKL may not support the 
actions of FGF23 in kidney, at least under pathologic conditions such as when Klotho or 
PHEX are deficient, or when FGF23 is overexpressed. In Hyp mice, an excess of osteocytic 
  
18 
 
FGF23 contributes to pyrophosphate accumulation and the resultant mineralization defect 
through the downregulation of tissue nonspecific ALP (Murali et al. 2016). In our models, 
the elevated levels of Furin mRNA in kidney may degrade FGF23, yielding more than a 100-
fold difference in FGF23 levels between bone and kidney. The abundant FGF23 in bone may 
thus provide a suitable environment for complex formation of sKL, FGF23 and FGFRs.  
 
Andrukhova and colleagues reported that FGF23 modulates PTH function via ERK1/2 
phosphorylation in bone and kidney (Andrukhova et al. 2016). The fact that sKL plus FGF23 
treatment upregulates ERK1/2 and Egr-1 in bone and osteoblastic cells is in keeping with the 
observation that they are involved in FGF23 signaling in kidneys, parathyroid and 
chondrogenic cells (Urakawa et al. 2006, Ben-Dov et al. 2007, Kawai M et al. 2013). 
However, results reported for ERK involvement in bone matrix mineralization have been 
somewhat contradictory, with ERK sometimes reported as a negative regulator and 
sometimes a positive regulator of matrix mineralization, likely due to the difficulty of 
completely separating the effects of ERK on osteoblast differentiation versus matrix 
mineralization in some models and protocols. For example, studies with transgenic mice 
overexpressing either a dominant negative Mek1 or constitutively active Mek1 driven by the 
osteocalcin promoter crossed with Runx2+/− mice suggested that ERK–MAPK activation 
stimulates osteoblast differentiation and skeletal development through a pathway involving 
RUNX2 (Ge et al. 2007). On the other hand, when Kono et al. used approaches of chemical 
inhibition and infection with adenovirus vector-mediated dominant negative Ras or 
constitutively active Mek1 in MC3T3-E1 cells, MLO-A5 pre-osteocytic cells and over the 
calvaria of neonatal mice, they concluded that ERK is a negative regulator of matrix 
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mineralization (Kono et al. 2007). Our results on calvaria cells specifically during the 
mineralization phase of cultures are in keeping with these latter results, and with the view 
that ERK activation acts as a negative regulator of bone matrix mineralization. That ERK 
may have apparently opposite effects at different stages of osteogenesis is consistent with a 
model in which the temporal rate and concentration of growth factors are captured by the Ras 
and Rap1 systems and encoded into transient or sustained ERK activation, respectively, to 
deliver distinct biological outcomes (Sasagawa et al. 2005). Additional studies to understand 
the dynamics of ERK activation in different stages of osteogenesis are warranted (see also 
below). 
 
The notion that ERK signaling has different effects at different stages of osteogenesis is 
paralleled by results with conditional inactivation of FGFR1 in osteogenic cells or in bones of 
transgenic mice that suggest a dual role for FGFR1 signaling at different stages of osteoblast 
maturation (Jacob et al. 2006). In osteo-chondroprogenitors or immature osteoblasts, FGFR1 
deficiency increased proliferation and delayed differentiation and matrix mineralization, 
whereas in differentiated osteoblasts, FGFR1 deficiency enhanced mineralization. On the 
other hand, FGF2 was reported to induce apoptosis in murine differentiating calvaria 
osteoblasts and in the calvaria suture of mice overexpressing FGF2 through FGFR2 
(Mansukhani et al. 2000). FGF2 also promoted proliferation in bone marrow stromal cells but 
inhibited alkaline phosphatase expression and matrix mineralization in mature osteoblasts via 
FGF23/FGFR/MAPK signaling (Xiao et al. 2013). Our data on sKL/FGF23-dependent ERK 
activation shows that activation is transient, which may explain why FGF23 but not FGF2 
acts on mineralization rather than osteogenic cell proliferation and apoptosis (Mansukhani et 
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al. 2000, Shalhoub et al. 2011, Xiao et al. 2013). It is also worth noting that PDZ-binding 
motif (TAZ) protein, the coactivator and repressor of the master transcription factors of 
osteogenesis (Runx2) and adipogenesis (PPARg), is negatively regulated by FGF2 via JNK 
signaling in mouse osteoblast MC3T3-E1 cells (Eda et al. 2008), while sKL/FGF23-
dependent hypomineralization requires the ERK pathway (Kyono et al. 2012). Fgf23 but not 
Fgf2 expression is markedly upregulated by 1,25D in osteoblasts/osteocytes, in parallel with 
the expression of the vitamin D receptor (Yamamoto et al. 2010). Taken together with the 
dynamics of FGFRs during osteoblastogenesis (Wang et al. 2008, Su et al. 2014), specific 
cellular settings may provide the specific context in which sKL and FGF23 act on bone 
mineralization.  
 
The expression of Phex, encoding a protein with homology to zinc metallopeptidases on the 
X chromosome, is mostly limited to osteoblasts/osteocytes and odontoblasts (Ruchon et al. 
2000). Loss-of-function mutations in Phex cause hypophosphatemia and hypomineralization 
in bones and teeth, possibly through accumulation of phosphaturic factors (Feng et al. 2013). 
Like kl/kl mice, Hyp mice show high levels of FGF23 (Nakatani et al. 2009). Little 
information is available on Klotho in XLH. Disruption of Klotho in Hyp mice (Klotho null-
Hyp) indicates that Klotho is epistatic to PHEX in biochemical parameters and lifespan 
(Brownstein et al. 2010). Taken together with our data on the dowregulation of Phex in bones 
of kl/kl mice treated with sKL, we propose the interdependence of FGF23, Klotho (sKL), and 
PHEX in skeletal homeostasis. It is possible that sKL treatment of Hyp mice may impact 
bone mineralization, but detecting such mineralization changes may be difficult, given that 
the downstream effector of sKL-FGF23, i.e., Phex, is inactive in Hyp mice. Our data may 
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connect two independent findings, that is, the 1,25D-dependent up- and downregulation of 
Fgf23 and Phex expression, respectively (Hines et al. 2004, Kolek et al. 2005, Barthel et al. 
2007). On the other hand, sKL treatment does not alter the gene expression levels of Spp1, 
Dmp1, and Mepe which are higher in kl/kl mouse bones compared by those in WT mice. This 
result indicates that hypomineralization of bones of kl/kl mice treated with sKL appears not to 
be mediated by these genes.  
 
In summary, treatment of kl/kl mice with sKL does not rescue their osteopenia, but rather 
suppresses bone mineralization. sKL participates in FGF23 signaling in bones of kl/kl mice, 
resulting in ERK1/2 activation and repression of PHEX, which is responsible at least in part 
for the intrinsic mineralization defects seen in kl/kl bone (Fig. 7).  
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Figure legends  
Figure 1 Recruitment of sKL increases ERK1/2 activation in parietal bones of kl/kl mice 
without changes in serum calcium and phosphate levels  
Serum FGF23 (A), calcium (Ca) (B), phosphate (Pi) (C), and 1,25D (C) levels. FGF23 levels 
in bones and kidneys (F). mRNA levels of Fgf23 in bones (E); Cyp27b1 (H), Slc34a1 (I), 
and Slc34a3 (J) in kidneys; Galnt3 (K), and Furin (L) in bones and kidneys. (G) ERK1/2 
phosphorylation in bones and kidneys. The following panels in (G) provide representative 
blotting images for each group. pERK1/2, phosphorylated ERK1/2. Values in (E, G–L) are 
relative to the wild-type (WT), which is set at 1.0. Data represent mean ± SD. * P < 0.05 and 
** P < 0.01, compared to WT mice. n = 9.  
 
Figure 2 A single intravenous administration of sKL to normal mice pretreated with 1,25D 
increased ERK1/2 activation in parietal bones 
Fgf23 mRNA levels in bones (A) and FGF23 levels in bones, kidneys (B), and sera (C). 
Serum calcium (Ca) (D) and phosphate (Pi) (E) levels. mRNA levels of Slc34a1 (F), Slc34a3 
(G), and Cyp27b1 (H) in kidneys. ERK1/2 phosphorylation in bones (I) and kidneys (J). 
pERK1/2, phosphorylated ERK1/2. Panels (I, J) are representative blotting images for each 
group. Values in (A, F–J) are relative to vehicle control is set at 1.0. Data represent mean ± 
SD. * P < 0.05 and ** P < 0.01, compared to vehicle control. # P < 0.05, compared to 1,25D 
alone. n = 6. -, vehicle control; D, 1,25D alone; D+sKL, 1,25D plus sKL, respectively. 
 
Figure 3 Recruitment of sKL caused hypomineralization in parietal bones of kl/kl mice 
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Representative images of frontal plastic (A, B) and decalcified paraffin (C) sections. (A) 
Elemental mapping of calcium (Ca), phosphorus (P), and magnesium (Mg). Right panel 
shows a color index for the level of each element. (B) Calcein-double labeling and calculated 
mineral apposition rate (MAR). (C) Hematoxylin and eosin staining. The parentheses in the 
figure indicate the osteoid. Scale bar, 5 µm (B) and 25 µm (C). Histomorphometry analysis 
of unmineralized osteoid thickness (OsTh) (D), number of osteoblasts per bone surface 
(NOb/BS) (E), osteocyte lacunae per bone area (NOc/BAR) (F), and bone thickness (BTh) 
(G). * P < 0.05 and * P < 0.01, compared to wild-type (WT) mice that received the vehicle. # 
P < 0.05, compared to kl/kl mice that received the vehicle. n = 9. 
 
Figure 4 Recruitment of Klotho increased ERK activation in the parietal bones of kl/kl mice 
(A) Representative images of immunofluorescence staining of FGF23-positive 
osteoblasts/osteocytes costained with anti-phosphorylated ERK (pERK) antibodies. 
Decalcified paraffin sections of parietal bones were used, as shown in Figure 3C. Scar bars, 
25 µm. (B–J) mRNA levels of osteoblast/osteocyte-associated genes. Values are relative to 
wild-type (WT) mice as controls that are set at 1.0. Data represent mean ± SD. * P < 0.05, 
compared to WT mice that received the vehicle. n = 9. 
 
Figure 5 sKL contributed to FGF23 signaling in bones, resulting in decreased matrix 
mineralization 
(A−D) Calvaria cell cultures of WT and kl/kl mice. Alkaline phosphatase-positive (ALP+) 
area (A) and mineralization foci (B). (C) FGF23 levels in culture media of WT and kl/kl as 
indicated in time (day). Data represent mean ± SD. * P < 0.05 and ** P < 0.01, compared to 
  
36 
 
WT mice. n = 8−9. (D) mRNA expression of Fgf23 and Klotho in bones and kidneys at day3 
(d3) and day10 (d10). (E-G) Parietal bones from newborn WT or kl/kl mice. (E) Medium 
FGF23 concentrations, Egr-1 mRNA levels (F), and ERK1/2 phosphorylation (G). Panels 
below (G) are representative blotting images for each group. Data represent mean ± SD. * P 
< 0.05 and ** P < 0.01, compared to matched vehicle control (−). n = 4. (H-J) Fetal rat 
calvaria cells. Egr-1 mRNA levels (H) and ERK1/2 phosphorylation (I). Panels below are 
representative blotting images for each group. (J) Immunoblotting (IB) with polyclonal anti-
FGF23 antibody (αFGF23) after immunoprecipitation (IP) with monoclonal anti-FGFR1 
antibody (αFGFR1). Data represent mean ± SD. ** P < 0.01, compared to matched vehicle 
control (−). n = 4. 
 
Figure 6 PHEX is a downstream target of sKL and FGF23 in the bones  
(A, E, F) The number of mineralized foci in fetal rat calvarial (RC) cell cultures. X-axis 
values in (A), µg/ml. (B-D) Phex mRNA levels in RC cells. Values are relative to matched 
controls, which is set at 1.0. (E) sPHEX, soluble PHEX. (F) U, U0126 (U); Dic, dicumarol; 
and SB, SB203580. Data represent mean ± SD.* P < 0.05 and ** P < 0.01, compared to 
matched vehicle control (−); # P < 0.05, compared to sKL/FGF23. n = 4. 
 
Figure 7 A schematic summary of the circulation and function of sKL and FGF23. 
sKL, truncated from membrane Klotho in kidneys, circulates and acts in bones but not 
kidneys, by forming a complex with FGFR1 and FGF23, which is expressed in bone. This 
upregulates ERK1/2 signaling, resulting in downregulation of Phex in osteoblasts-osteocytes 
and resultant hypomineralization of bone. 
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Supplementary Figure 1 Serum FGF23 levels with body weight changes in WT vs kl/kl 
mice 
(A) Serum FGF23 levels in WT and kl/kl mice at day 7, 21, 30, and 42. (B) Body weight 
changes in WT and kl/kl mice with and without sKL at day 10, 13, 16, 19, and 22. Data 
represent mean ± SD. * P < 0.05 and *** P < 0.001, compared to WT mice. n = 9−10. 
 
Supplementary Figure 2 The RGB color intensity of electron probe X-ray microanalysis of 
parietal bones 
Quantification of the RGB (red, green, and blue) color intensity of the representative image 
shown in Figure 3A. Values are relative to WT mouse bones, which is set at 1.0. 
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Supplementary Table 1
Species Target Sequence Size
F CTG CAA GGA CAT CGC CTA TC
R CAT CAG TTC TGT TCT TGG GGT A
F CCT ATG AGC ACC TGA CCA CA
R AGG CCA CTG ACT AGG CTG AA
F TAA TAG GGG CCA TGA CCA GA
R TGA TGC TTC GGT GAC AGG TA
F GGGACCACCAGAAGAGATGA
R TTGGCTACAACCCCGTCTAC
F CCT CCT ACC AGG CAT CAC AT
R GGA GGA CTG TGA GCA CCA AT
F GAT TCA AGG GCC AGA TCC T
R GCA TGT GCT TGG TTT TCT TG
F TTT TCC AGC CTT CCT TCT TG
R ACG GAT GTC AAC GTC ACA CT
F TGG CCT GGA TCT CAT CAG TA
R GTG CGG TTC CAG ACA TAG TG
F AAG CAG GAG GGC AAT AAG GT
R ACT TGC AGG GCA GAG AGA GA
F CAG CTT CCT GGC TGA ACT CT
R GAC CAT ATT GGC CCG TAC C
F CCC ACG AAC AGT GAG TCA TC
R GCT GTC CGT GTG GTC ACT AT
F CAA CCG GTA CCT TGC TAT GA
R TCC GTG ACC GGT AAG TAT TG
F TTT GGA TCG CTT CAC TTC AGC
R ACC AGG TAG TGA TGC TTC TGC
F TTT AAG CCT GAC CAC CGA AT
R TCA GAA GGC ACC ACA GAA TC
F CCA CCA AGC CCT TTC TAA CA
R TGC AAA AGG CAC ATC AGA AG
F GGA GGC AAA CCA TTG ATT CT
R CGC TGA GCA GAA TAC TCG AA
F CAA AAG GGA TGA TGC CAA AT
R CTG TAG CCC CTA TGC CAC TC
F CTC ATG AAG ATG CAG GCT GT
R CAG CTG CTC CTG TCT TCA TT
F CCA TGA GAT TGG CAG TGA TT
R CTC CTC TGA GCT GCC AGA AT
F ATT GCA CTG GCC CTG TTT AT
R GCT TGG AAA CTT AGG AGA CCT T
F AGT TCA TCA GGC ACC AGT CA
R TGT CAA TGC CTC TGG GTT T
F CTC ATT GTG GGT GCC CAA CAT GAT G
R ACC ATG TGT CTC CCA CGG ACT GGA AG
F CCA GCT GGA TAG CAG TGT GA
R TGT CCT CCT CTG GAG ATG CT
F AAG GGA GTG TGG AAC GAA AG
R GGT CAG GGT CAG AAA CCC TA
Rat
Mouse
Alp 101
196
437
145
Egr-1
Fgf23
Klotho
Phex
Rpl32 66
126
89
Klotho
75
93
274
Actb
Alp
Bglap
Cyp27b1
Dmp1
75
Fgf2
Fgf23
Fgfr1
Furin
Galnt3
Mepe
Sost
Slc34a3
Slc34a1
Rpl32
Opn
Phex
112
119
101
83
90
74
144
89
89
72
90
173
86
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Supplementary Table 2
b-gal FGF23 b-gal FGF23
RT1-EC2 18.3 50.2 1.7 Rdx 250.8 97.1 -1.3
Transcribed locus 59.7 167.2 1.4 Phex 133.9 68.3 -1.2
Transcribed locus 384.5 997.7 1.4 Transcribed locus 251.3 105.7 -1.2
Egln3 13.1 31.9 1.4 Zfp422 108.6 58.9 -1.2
Slx1b 55.3 153.9 1.3 Transcribed locus 38.3 17 -1.2
S100a13 53.6 154.3 1.3 Fgl2 34.5 12.7 -1.2
RT1-EC2 10.1 24.9 1.3 Transcribed locus 205.8 96.7 -1.2
Gnb1 99.4 271 1.3 Ythdf2 628.7 247.1 -1.1
Cdkn1a 238.1 500.6 1.3 Transcribed locus 91.6 43.8 -1.1
Transcribed locus 204.4 456.9 1.2 Dusp6 111.5 48.5 -1.1
Transcribed locus 63.6 190.3 1.2 Transcribed locus 145.5 62.4 -1.1
Mnf1 269.3 624.4 1.2 Transcribed locus 65.6 33 -1.1
Cklf 22.8 54.4 1.2 Lin7c 232.2 120.4 -1
Atox1 185.5 425.3 1.2 Transcribed locus 749 386.2 -1
(miscRNA) 64.6 131.5 1.2 Transcribed locus 67.1 44.1 -1
Ubl7 63.4 124.9 1.1 Transcribed locus 76.4 37.9 -1
RGD1565641 265.8 663.2 1.1
Lcp1 11.7 28.6 1.1
Emg1 74.4 144 1.1
Usmg5 931.1 1821.5 1
Transcribed locus 33.6 67.9 1
TL0ABA24YI10 436.4 775.6 1
Slirp 200.6 410.5 1
Rps25 1364.4 2846.6 1
RGD1309621 555.2 1161 1
RGD1309621 259.3 447.6 1
Polr2l 337.7 538.4 1
Polr2i 245.5 489.6 1
Nop10 772.2 1506.6 1
Ndufa11 407.7 844.9 1
Mrpl14 29.1 50.5 1
Eif3k 604.9 1283.7 1
Csde1 440 871.6 1
Churc1 432.1 909.2 1
Atp5j2 632.8 1253.6 1
Upregulated Downregulated
Intensity Fold
change
IntensityGene Fold change
(log)
Gene
